Meet this Newcastle University scientist who donated all her royalty money to improve cancer research in India – EdexLive
Posted: May 16, 2020 at 3:48 am
The danger of cancer continues to cast a shadow of fear in the lives of Indian women. According to experts, the women being diagnosed grow younger by day compared to the same in developed countries. UK-born Dr Asima Mukhopadhyay is a clinician-scientist in womens cancer. Having set up the Project Ovarian Transnational Group of Studies in Kolkata in 2015 and the Kolkata Gynecological Oncology Trials and Translational Research Group, the first-ever research group from India to become a member of the Gynecological Cancer Intergroup, she is one of the leading voices in women's cancer research and in the country. This year, she donated her royalty money as a co-developer of the PARP inhibitor Rucaparib (an anti-cancer drug) to build research capacity for cancer in India. We spoke to her about what needs to be done in cancer research in the country and how we can ensure that treatment reaches the people who need it the most. Excerpts:
What is the current status of women's cancer care in India? Could you outline the areas where we need to move ahead?
The keys areas where we need to move ahead are public awareness through media and community-based programmes. School and college health education would be a major step in ensuring that women with symptoms get to see a cancer specialist in regional cancer centres in the first place rather than reaching thereafter a significant financial drain and loss in valuable time or inadequate treatment. Secondly, we need more trained specialists and dedicated organ-specific cancer teams capable of addressing our specific needs. We also need preventive measures like vaccination, screening, genetic testing and risk-reducing surgeries, as well as ensuring access to life-saving cancer drugs and treatment options.
What led you to make the decision to donate your royalty payment?
On a personal front, I decided on a career in cancer care and research after the demise of my father at a relatively young age in 1998 due to cancer. It was not so long after that I had graduated from Medical College Kolkata. As a cancer survivor family and a young budding doctor, I had the first-hand experience of the emotional, social and economic turmoil and helplessness that one has to undergo to fight this disease and the need for better treatment options and research towards this.
After my return to India in 2015 from the UK, I had joineda reputed cancer centre in Kolkata as an onco-surgeon; I noticed that in India, a majority of cancer patients are not aware of the need to participate in studies or clinical trials which automatically improves the quality of care. In countries like the UK, major cancer research organisations are heavily supported through public funding and donations. We need similar support mechanisms in India including media support and goodwill for promoting better patient care.
Could you describe your discovery around epithelial ovarian cancer and the implications it has for treating cancer?
It had been previously shown by the Newcastle University group of researchers in the UK and various other groups that cancers harbouring a genetic defect in the BRCA genes are very sensitive to a new class of anti-cancer drug called PARP inhibitors. I joined this group in 2008 as a clinician-researcher for my PhD. In 2010, I showed that approximately that 50% epithelial ovarian cancer patients harbour a defect called BRCAness or homologous recombination deficiency (HRD), therefore providing the scope for extending the use for PARP inhibitors to a lot more women compared to only 10-20% of women who have inherited detects in the BRCA gene.
In 2011, this was published as the first-ever report showing the importance of functional BRCAness. I developed a functional biomarker assay (used to understand the mechanism of action of a drug) using ascitic fluid from ovarian cancer patients at the Northern Gynaecological Oncology Centre in Gateshead. After 10 years of my original publication, there is a renewed interest in adopting the functional HRD assay as a better biomarker for selecting patients suitable for PARP inhibitor therapy.
Are women in India at a position where they can seek medical help successfully? How do we spread more gynaecological awareness among the general public?
Partially, yes. There are health systems available and women can seek proper medical health at the tertiary centres. However, many primary and secondary health centres are not much developed and we often find patients referred to us with partial or incomplete treatment. The need of the hour is to train the trainer. Healthcare workers should be trained regarding various cancers, their symptoms, risk factors, hereditary factors and their preventive and treatment opportunities, so that they are able to identify the population at risk of cancers and create health education camps for enlightening the population.
School health awareness campaigns can be created so that children of ages 12 years and above are educated regarding breast self-examination, menstrual hygiene, personal hygiene, obesity and hereditary cancer history so that they are aware of their physical and hereditary risks and act accordingly to prevent cancers in future. These children are the future of our society and if we can incorporate the knowledge of health awareness, the cancer risk in women will sufficiently decrease in future. I firmly believe that if we can incorporate such community-based awareness and screening camps integrated within the existing governmental structures, the access of women from low-income households will surely increase.
See more here:
Meet this Newcastle University scientist who donated all her royalty money to improve cancer research in India - EdexLive
- Last Call with Jenna Balestrini, the WPI grad treating cancer with cell therapy - Worcester Mag - January 14th, 2021
- Province gives family facing $2.8M drug bill a glimmer of hope - CBC.ca - January 14th, 2021
- New Combination Therapy Tested By Children's May Offer Hope For Leukemia Patients - WVXU - December 22nd, 2020
- This 6-year-old Iowa boy is losing his vision and hearing. But his family holds on to hope. - The Gazette - December 22nd, 2020
- What Is Gene Therapy? How Does It Work? | FDA - December 17th, 2020
- What is gene therapy? - The Star Online - December 17th, 2020
- What It's Like Rising A Little Boy With Advanced Breast Cancer - Oprah Mag - December 17th, 2020
- EAPM Advancing gene therapy with Advanced Therapy Medicinal Products - EU Reporter - December 16th, 2020
- San Diego's Locanabio raises $100 million for treatments aimed at degenerative diseases - The San Diego Union-Tribune - December 16th, 2020
- Italy needs new restrictions to avoid third, devastating COVID-19 wave - PM to paper - EU Reporter - December 16th, 2020
- Yes, men can get breast cancer here are the symptoms to watch for - Insider - INSIDER - December 12th, 2020
- Mumbai: Baby with genetic disorder needs Rs 16 crore therapy to live - Mid-day - December 12th, 2020
- Gene Therapy Liberates Hemophilia B Patients from Requiring Regular Infusions of Clotting Factor - MedicalResearch.com - December 12th, 2020
- Vaccination in the Era of Covid - Touro College News - December 7th, 2020
- Genentech Announces New Data Reinforcing the Long-Term Benefit of Venclexta-Based Combination for People With Relapsed or Refractory Chronic... - December 7th, 2020
- Medicare and cystic fibrosis: Coverage, options, treatments, and costs - Medical News Today - December 7th, 2020
- The FDA has approved the first drug to treat the rapid-aging disease progeria - Science News - November 26th, 2020
- 'This is why I'm here': A Detroit Lions VP tries to save her daughter from rare disease - ESPN - November 24th, 2020
- Encouraging Clinical Data for Controlled IL-12 for the Treatment of Glioblastoma and DIPG - OncoZine - November 24th, 2020
- SwanBio Therapeutics Expands Board of Directors with Appointments of Proven Industry Leaders - Business Wire - November 24th, 2020
- SwanBio Therapeutics Expands Board of Directors with Appointments of Proven Industry Leaders - BioSpace - November 23rd, 2020
- Rare Mutation in the PCSK9 Gene Confers Long Healthy Life - MedicalResearch.com - November 23rd, 2020
- Living through the second wave - Pakistan Today - November 23rd, 2020
- How two blind brothers became Two Blind Brothers for a cause - The Columbian - November 10th, 2020
- How two blind brothers created a one-of-a-kind shopping experience to raise money for a cure - WXII The Triad - November 10th, 2020
- The ethical way to alter organisms - The Boston Globe - November 10th, 2020
- Teladoc Is A Strong Buy: A Radical Healthcare Change Will Come - Seeking Alpha - November 10th, 2020
- Medical Milestone In Boston: 13-Year-Old Gets New Gene ... - November 5th, 2020
- How immunotherapy is revolutionizing cancer care - Genetic Literacy Project - October 29th, 2020
- The good news about breast cancer - The Gazette - October 29th, 2020
- Harris County parents win insurance appeal for 8-year-olds MD treatment - WRBL - October 29th, 2020
- Biohack the ageing process by taking care of this little protein in your body - Lifestyle Asia - October 22nd, 2020
- 'I have faith and I prayed a lot' - News from southeastern Connecticut - theday.com - October 22nd, 2020
- Piqray Improves Overall Survival for Advanced-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer With PIK3CA Mutation - Breastcancer.org - October 20th, 2020
- Beating Cancer: Prevention must be 'cornerstone' of EU's new approach - The Parliament Magazine - October 20th, 2020
- Watch: New 5-minute injection a game-changer in breast cancer therapy in UAE - Gulf News - October 20th, 2020
- Homer Glen Mom and Nurse Breast Cancer-Free after Radiation Therapy Clinical Trial at UChicago Medicine Comprehensive Cancer Center at Silver Cross -... - October 20th, 2020
- Teenager among first to receive gene therapy treatment for rare condition - KRDO - October 8th, 2020
- Proposition 14: With Just Handful of Cures, California Stem Cell Agency's Fate Is In Hands of Voters - KQED - October 8th, 2020
- Teenager among first to receive gene therapy treatment for rare condition - NewsChannel 3-12 - KEYT - October 7th, 2020
- Greenbrier County teen to be among first in nation to receive gene therapy for Hurler's Syndrome - WVVA TV - October 7th, 2020
- Regenxbio RGX-121 Clinical Program, And Other News: The Good, Bad And Ugly Of Biopharma - Seeking Alpha - October 7th, 2020
- Women In Longevity Medicine And The Rise Of The Longevity Physician - Forbes - October 7th, 2020
- Timothy Ray Brown, First Patient to Be Cured of HIV, Dies of Leukemia - BioSpace - October 7th, 2020
- Different Types of Childhood Cancer | INTEGRIS - Integris - October 4th, 2020
- Gene therapy company Taysha completes sprint from first funding to IPO - BioPharma Dive - September 26th, 2020
- Focused on the future: Innovative college programs in N.J. pave way for the real world - Jersey's Best - September 24th, 2020
- Burosumab Is a 'Game Changer,' Effective in All Subgroups of XLH - Medscape - September 22nd, 2020
- 10 Forgotten Spiderman Sidekicks They Need To Bring Back | CBR - CBR - Comic Book Resources - September 22nd, 2020
- Genentech Presents New Data From Multiple Phase III Studies of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020 - Business... - September 21st, 2020
- BCS Announces Partnership With 2nd.MD to Improve Member Healthcare Cost, Quality, and Outcomes - PRNewswire - September 19th, 2020
- Novus Therapeutics Announces Acquisition of Anelixis Therapeutics - Business Wire - September 19th, 2020
- Pace toddler wasn't supposed to survive. Thanks to wonder drug, parents say he's thriving - Pensacola News Journal - September 8th, 2020
- CRISPR can help combat the troubling immune response against gene therapy - The Conversation US - September 6th, 2020
- How Is Ovarian Cancer Diagnosed? Everything You Need To Know - NDTV Doctor - September 6th, 2020
- Genentech Announces FDA Approval of Gavreto (pralsetinib) for the Treatment of Adults With Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer |... - September 6th, 2020
- Gilmore Health: A Q&A Session on Genetic Diseases With Dr. Sony Sherpa - Gilmore Health News - September 6th, 2020
- Our teenage son is turning to stone and is becoming entombed in his own body - The Sun - August 28th, 2020
- Gene Therapy: IT Meets Medicine, But Who Is In Charge? - Walter Bradley Center for Natural and Artificial Intelligence - August 24th, 2020
- Edited Transcript of ISEE.OQ earnings conference call or presentation 5-Aug-20 12:00pm GMT - Yahoo Finance - August 6th, 2020
- Opinion: With any COVID-19 vaccine, humanity will face its biggest moral test - The Province - August 4th, 2020
- These Companies Are Seeking a Cure for Sickle Cell. And Its Just the Beginning for Some Gene Therapy Stocks. - Barron's - July 31st, 2020
- FDA Approves Combination Therapy for Treating Advanced Melanoma - Pharmacy Times - July 31st, 2020
- How Can Technology Help Fight the COVID-19 Pandemic? - IoT For All - July 31st, 2020
- Thomas Jefferson University doctor to be honored at W&J commencement - Observer-Reporter - July 30th, 2020
- First Edition: July 27, 2020 - Kaiser Health News - July 30th, 2020
- These are the most valued tech startups in France in 2020 - Silicon Canals - July 7th, 2020
- What's a life worth in dollars and cents? Should that influence who gets treated for expensive disease treatments? - Genetic Literacy Project - July 1st, 2020
- FDA Approves Genentech's Phesgo (Fixed-dose Combination of Perjeta and Herceptin for Subcutaneous Injection) for HER2-positive Breast Cancer -... - July 1st, 2020
- Conversations Between Patient and Oncologist Are Important in Avoiding 'Common Mistake' When Treating CLL - Curetoday.com - June 28th, 2020
- Drug used in breast and ovarian cancer could lead to safer, more effective treatment for neuroblastoma - The Institute of Cancer Research - June 28th, 2020
- Family Of Dying Santa Clarita Teen Pleads With Community For Donations To Fund Life-Saving Treatment - KHTS Radio - June 24th, 2020
- Hungarian Neurobiologist Botond Roska to Receive This Year's Krber European Science Prize - Hungary Today - June 24th, 2020
- Quarterly summary: the COVID-19 lockdown and the importance of scientists - University Affairs - June 24th, 2020
- Flames assistant GM continues to defy the odds in his battle against ALS - CTV News - June 23rd, 2020
- 3 Reasons to Go Long Crispr Therapeutics - InvestorPlace - June 23rd, 2020
- GRIN Disorder, Kidney Failure and Fathers Day How One Family is Surviving it All - CBC.ca - June 23rd, 2020
- Gene Therapy: Regal Profits From Curing "The Royal Disease"? - Sick Economics - June 18th, 2020
- Cancer patients and doctors carry on with clinical trials during Covid-19 - STAT - June 18th, 2020
- Genentech's Tecentriq in Combination With Chemotherapy (including Abraxane) Meets Primary Endpoint of Improved Pathological Complete Response,... - June 18th, 2020